TRVI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
Šios dienos apimtis	84 086.00
Vidutinė apimtis	307 547
Rinkos kapitalizacija	207.57M
EPS	$0 ( 2024-03-20 )
Kita pelno data	( $-0.0900 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.38
ATR14	$0.00700 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-15	Galletta Christopher	Buy	28 500	Stock Option (right to buy)
2024-02-15	Simon Farrell	Buy	175 000	Stock Option (right to buy)
2024-02-15	Clark David J	Buy	175 000	Stock Option (right to buy)
2024-02-15	Good Jennifer L	Buy	630 000	Stock Option (right to buy)
2024-02-15	Sciascia Thomas	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
78.47
Last 98 transactions
Buy: 31 017 280 \| Sell: 1 379 035

Tūris Koreliacija

Ilgas: -0.16 (neutral)

Trumpas: 0.25 (neutral)

Signal:(56.931) Neutral

Trevi Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Trevi Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.55
( weak negative )

-0.52
( weak negative )

0.00
( neutral )

-0.30
( neutral )

0.60
( weak )

-0.45
( neutral )

Trevi Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2023
Pajamos:	$0
Bruto pelnas:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2022
Pajamos:	$0
Bruto pelnas:	$-43 000.00 (0.00 %)
EPS:	$-0.450

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.